BioKangtai(SZ:300601) Sou Hu Cai Jing·2025-07-31 14:04Core Viewpoint - As of July 31, 2025, Kangtai Biological (300601) reported a closing price of 17.42 yuan, experiencing a decline of 1.86% with a turnover rate of 3.05% and a trading volume of 274,300 hands, amounting to 484 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, the company reported total operating revenue of 645 million yuan, representing a year-on-year growth of 42.85% [1] - The net profit attributable to shareholders was 22.43 million yuan, a decrease of 58.51% year-on-year [1] - The non-recurring net profit was 16.91 million yuan, showing a year-on-year increase of 17.56% [1] - The current ratio stood at 2.677, the quick ratio at 2.365, and the debt-to-asset ratio at 32.07% [1] Capital Flow - On the reporting day, the net outflow of main funds was 61.05 million yuan, accounting for 12.6% of the transaction value [1] - The net outflow from large orders was 17.58 million yuan, representing 3.63% of the transaction value, while small orders saw a net inflow of 46.24 million yuan, accounting for 9.55% [1] Company Overview - Shenzhen Kangtai Biological Products Co., Ltd. was established in 1992 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 11.17 billion yuan and a paid-in capital of 1.75 billion yuan [1] - The legal representative of the company is Du Weimin [1] Investment and Intellectual Property - The company has made investments in 6 enterprises and participated in 1,088 bidding projects [2] - It holds 13 trademark registrations and 57 patents, along with 418 administrative licenses [2]